Copyright ©2022 by PanNash™ Initiative – All rights reserved.
We have an interesting experimental paper in press at the moment at the Journal of Hepatology. Analyzing the role of different selective PPAR agonists in experimental models of steatohepatitis and liver diseases. In this paper, we are able to show that the different isoforms of people which are transcription factors present in different cell types actually jointly affect the progression of liver diseases if stimulated, so if we treat mice in different models of non-alcoholic fatty liver disease and NASH (non-alcoholic steatohepatitis), we are able to demonstrate that stimulating several PPARS forms at the same time by a pan PPAR Agonist called lanifibranor is more effective than the selective stimulation and actually combines positive beneficial metabolic effects and anti-fibrotic. Of the selective pragmus this paper is impressive at the moment at the Journal of Hepatology, and I’m looking forward to its publication.